Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Kyung-Sang Yu"'
Publikováno v:
Drug Design, Development and Therapy
Sungyeun Bae,1 Jihoon Kwon,2 Si-Beum Lee,3 In-Jin Jang,1 Kyung-Sang Yu,1 SeungHwan Lee1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Statistics Team, APA
Autor:
Jung Yoon Choi, Kyung Sang Yu, In-Jin Jang, Joo Youn Cho, Seol Ju Moon, Hyoung Jin Kang, Jaeseong Oh, Soyoung Lee, Kyung Taek Hong, Che Ry Hong, Hee Young Shin
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:293-301
A long-acting granulocyte colony-stimulating factor, tripegfilgrastim, was approved in Korea for the prevention of chemotherapy-induced neutropenia in adult patients. In this study, we evaluated the pharmacokinetics, pharmacodynamics, and safety of t
Autor:
Jung Bin Cha, Jong Lyul Ghim, Yun Ju Bae, In Sun Kwon, Hyeong Seok Lim, Sung-Hyun Kim, In-Jin Jang, Daniel E. Furst, Kyung Sang Yu, Sang Joon Lee, Jae Yong Chung, Doo-Yeoun Cho, Edward C. Keystone, Min Kyu Park, Jang Hee Hong, Min Soo Park, Jonathan Kay, Min-Gul Kim, Seung-Hwan Lee, Seok Kyu Yoon
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1280-1291 (2021)
Clinical and Translational Science
Clinical and Translational Science
This study aimed to demonstrate pharmacokinetic (PK) equivalence of a single dose of the proposed adalimumab biosimilar CT‐P17 to United States‐licensed adalimumab (US‐adalimumab) and European Union‐approved adalimumab (EU‐adalimumab). This
Autor:
Seon‐Jae Ahn, Jaeseong Oh, Do‐Yong Kim, Hyoshin Son, Sungeun Hwang, Hye‐Rim Shin, Eun Young Kim, Han Sang Lee, Woo‐Jin Lee, Jangsup Moon, Soon‐Tae Lee, Keun‐Hwa Jung, Kyung‐Il Park, Ki‐Young Jung, SeungHwan Lee, Kyung‐Sang Yu, Kon Chu, Sang Kun Lee
Publikováno v:
EpilepsiaREFERENCES. 63(11)
Many pharmacokinetic studies of lacosamide (LCM) have been reported, but no large-scale clinical study has been conducted on genetic polymorphisms that affect the metabolism of LCM. Therefore, we designed a pharmacogenetic study of LCM to explore the
Autor:
Hong Keun Chung, Seung-Hwan Lee, Kyung Sang Yu, In-Jin Jang, Sun-Young Lee, Byong Yeul Han, Yun Kim, Mu Seong Ban
Publikováno v:
Clinical Pharmacology in Drug Development. 10:1358-1364
Natural protopanaxadiol ginsenosides exhibit low absorption in the human intestine. However, ginsenoside compound K (CK) with 1 conjugated glucose molecule exhibits favorable absorption. The purpose of this study was to compare the pharmacokinetics o
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 58:354-362
Objective Asthma patients often have co-existing symptoms of allergic rhinitis and are often prescribed with both asthma and rhinitis treatments such as montelukast and levocetirizine. The objective of this study was to compare the pharmacokinetic pr
Publikováno v:
Drug Design, Development and Therapy
Seol Ju Moon,1,2Ji-Young Jeon,1 Kyungho Jang,1 Kyung-Sang Yu,2 Yeji Lim,3 Min-Gul Kim1,4–51Center for Clinical Pharmacology, Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Republic of Korea; 2Department of Clinical Pha
Autor:
Kyung Sang Yu, Deok Yong Yoon, Seo Hyun Yoon, Seung-Hwan Lee, Hyounggyoon Yoo, In-Jin Jang, Sang Won Lee, Joo Youn Cho
Publikováno v:
Clinical therapeutics. 43(3)
Purpose Ranolazine, an inhibitor of late inward sodium current, is an antianginal agent. In this study, the pharmacokinetic (PK) properties and tolerability of single- and multiple-dose ranolazine were compared between healthy Korean and white subjec
Publikováno v:
Journal of Korean Medical Science
Background The number of clinical trials conducted in Korea continues to increase and an increasing proportion focus on severe and rare incurable diseases. After the start of the severe acute respiratory syndrome, coronavirus disease 2019 (COVID-19),
Autor:
Jung, Sunwoo, Sang Chun, Ji, Jaeseong, Oh, Mu Seong, Ban, Ji Yeon, Nam, Bongtae, Kim, Geun Seog, Song, Kyung-Sang, Yu, In-Jin, Jang, SeungHwan, Lee
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 52(11-12)
Potassium-competitive acid blockers (P-CABs) are emerging as novel treatments for acid-related disorders including gastroesophageal reflux disease. Tegoprazan and revaprazan are approved P-CABs in South Korea, but the pharmacodynamics and safety/tole